Skip to content

Study · Animal study (in vivo) · mouse · 2011

12 results

Treatment with a melanocortin agonist improves abnormal lipid metabolism in streptozotocin-induced diabetic mice.

Leckstrom A, Lew PS, Poritsanos NJ, Mizuno TM

Neuropeptides8 Jan 2011Cited by 2 (Europe PMC)

PMID21216462 (opens in a new tab)DOI10.1016/j.npep.2010.12.005 (opens in a new tab)PepBankPUB-21216462
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In STZ-induced diabetic mice, central MTII did not improve hyperglycemia.

    In plain wordsIn diabetic mice, MTII given into the brain did not improve high blood sugar.

    Peptide
    Melanotan II
    Outcome
    No significant changeSTZ-induced hyperglycemia
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    STZ-induced hyperglycemia and glucose intolerance were not improved by MTII treatment.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In STZ-induced diabetic mice, central MTII did not improve glucose intolerance.

    In plain wordsIn diabetic mice, MTII given into the brain did not improve glucose tolerance.

    Peptide
    Melanotan II
    Outcome
    No significant changeGlucose intolerance
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    STZ-induced hyperglycemia and glucose intolerance were not improved by MTII treatment.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not alter hepatic expression of glucose-6-phosphatase.

    In plain wordsIn diabetic mice, MTII given into the brain did not change liver activity of the G6Pase gene.

    Peptide
    Melanotan II
    Outcome
    No significant changeHepatic G6Pase mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment did not alter expression levels of genes encoding gluconeogenic enzymes including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), in the liver of diabetic mice.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not alter hepatic expression of phosphoenolpyruvate carboxykinase.

    In plain wordsIn diabetic mice, MTII given into the brain did not change liver activity of the PEPCK gene.

    Peptide
    Melanotan II
    Outcome
    No significant changeHepatic PEPCK mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment did not alter expression levels of genes encoding gluconeogenic enzymes including glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), in the liver of diabetic mice.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not alter skeletal muscle GLUT4 mRNA levels.

    In plain wordsIn diabetic mice, MTII given into the brain did not change GLUT4 gene activity in muscle.

    Peptide
    Melanotan II
    Outcome
    No significant changeSkeletal muscle GLUT4 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Skeletal muscle and white adipose tissue glucose transporter 4 (GLUT4) mRNA levels were not altered by MTII treatment in diabetic mice.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not alter white adipose tissue GLUT4 mRNA levels.

    In plain wordsIn diabetic mice, MTII given into the brain did not change GLUT4 gene activity in fat tissue.

    Peptide
    Melanotan II
    Outcome
    No significant changeWhite adipose tissue GLUT4 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Skeletal muscle and white adipose tissue glucose transporter 4 (GLUT4) mRNA levels were not altered by MTII treatment in diabetic mice.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, central MTII significantly reduced serum nonesterified fatty acid levels, which were raised in diabetic mice.

    In plain wordsIn diabetic mice, MTII given into the brain lowered blood levels of free fatty acids.

    Peptide
    Melanotan II
    Outcome
    DecreaseSerum NEFA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Comparator
    Untreated diabetic mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, serum nonesterified fatty acid (NEFA) levels were significantly increased in STZ-induced diabetic mice compared to non-diabetic control mice and MTII treatment significantly reduced serum NEFA levels in diabetic mice.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced hormone sensitive lipase mRNA in white adipose tissue.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the HSL fat-breakdown gene in fat tissue.

    Peptide
    Melanotan II
    Outcome
    DecreaseWhite adipose tissue HSL mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment also significantly reduced expression levels of hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) mRNA in white adipose tissue of diabetic mice without a significant change in serum insulin levels.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced adipose triglyceride lipase mRNA in white adipose tissue.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the ATGL fat-breakdown gene in fat tissue.

    Peptide
    Melanotan II
    Outcome
    DecreaseWhite adipose tissue ATGL mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment also significantly reduced expression levels of hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) mRNA in white adipose tissue of diabetic mice without a significant change in serum insulin levels.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, central MTII caused no significant change in serum insulin levels.

    In plain wordsIn diabetic mice, MTII given into the brain did not change blood insulin levels.

    Peptide
    Melanotan II
    Outcome
    No significant changeSerum insulin
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    without a significant change in serum insulin levels.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not change lipoprotein lipase mRNA in white adipose tissue and skeletal muscle.

    In plain wordsIn diabetic mice, MTII given into the brain did not change LPL gene activity in fat tissue and muscle.

    Peptide
    Melanotan II
    Outcome
    No significant changeLPL mRNA in white adipose tissue and skeletal muscle
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Expression levels of lipoprotein lipase (LPL) and fatty acid translocase (FAT/CD36) mRNA in white adipose tissue and skeletal muscle were not changed by MTII treatment.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII did not change fatty acid translocase mRNA in white adipose tissue and skeletal muscle.

    In plain wordsIn diabetic mice, MTII given into the brain did not change CD36 gene activity in fat tissue and muscle.

    Peptide
    Melanotan II
    Outcome
    No significant changeFAT/CD36 mRNA in white adipose tissue and skeletal muscle
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Expression levels of lipoprotein lipase (LPL) and fatty acid translocase (FAT/CD36) mRNA in white adipose tissue and skeletal muscle were not changed by MTII treatment.
    1 context sentence
    Summary · context
    To address this hypothesis, streptozotocin (STZ)-induced diabetic mice were treated with daily intracerebroventricular injection of MTII, a melanocortin agonist, for 11days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.